Health Care·Biotechnology·$33.4B
Beone Medicines Ltd ADR operates in the biotechnology sector, focusing on developing innovative therapies for various health conditions. With a market cap of $33 billion, the company plays a significant role in advancing healthcare solutions, particularly in a landscape increasingly driven by biopharmaceutical advancements.
EPS
Earnings per share is a key indicator of profitability and will show how well the company is managing its expenses relative to its revenue.
Revenue
Total revenue reflects the company's ability to generate sales and is crucial for assessing growth and market demand for its products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
4Q
EPS Beat Rate
80%
Avg EPS Surprise
+578.70%
Avg Stock Reaction
-0.87%
In the last quarter, Beone Medicines reported an EPS of $1.95, significantly exceeding expectations, which indicates strong performance. However, the stock experienced a decline of 8.48% the following day, suggesting market volatility despite positive earnings.
Management Promises & Guidance
Analysts expect Beone Medicines to report solid earnings this quarter, with a consensus EPS of $0.87 and revenue of $1.4 billion. The market is closely watching how the company performs against these estimates given its recent strong earnings history.
Bull Case
If Beone Medicines exceeds EPS expectations, it could indicate robust demand for its products and effective cost management, potentially leading to a positive stock reaction.
Bear Case
Conversely, if the company misses its EPS or revenue targets, it could raise concerns about its growth trajectory and market competitiveness, leading to a negative stock response.
EPS
$0.87Earnings per share is a key indicator of profitability and will show how well the company is managing its expenses relative to its revenue.
Revenue
$1.4BTotal revenue reflects the company's ability to generate sales and is crucial for assessing growth and market demand for its products.
The print will turn on these two things.
Q1
Will Beone Medicines achieve an EPS of at least $0.87?
This figure is critical for assessing the company's profitability and growth potential, and a beat could boost investor confidence.
Q2
What will be the revenue figure, and how does it compare to the $1.4 billion consensus?
Revenue performance is essential for understanding market demand and the company's ability to scale, impacting future growth prospects.
Why consensus could be wrong
The Street may be underestimating the impact of recent product launches, which could drive higher-than-expected revenue growth this quarter.
Supporting Evidence
The company has a strong track record of beating EPS estimates, with an 80% beat rate over the last five quarters.
Options pricing suggests a larger move than historical averages, indicating heightened investor expectations.
Recent industry trends show increasing demand for innovative therapies, which could benefit Beone Medicines.
Key Risk
If revenue exceeds $1.5 billion, it could significantly shift market sentiment and expectations for future growth.
Pre-commit to what would confirm each case.
This quarter's performance will be closely scrutinized as it follows a series of strong earnings surprises, and market sentiment is sensitive to any signs of weakness.
Bull Confirmed If
An EPS of $0.95 or higher would confirm strong operational performance and market demand.
Bear Confirmed If
An EPS below $0.70 would raise concerns about profitability and growth sustainability.
Implied Move
±8.03%
Historical Avg
±5.2%
The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.
Options are pricing ±8.0% while ONC has averaged ±5.2% over the last 5 prints — setup is pricing rich.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Beone Medicines beats expectations, history suggests a potential average move of +2.96% the next day, confirming strong market demand.
In-Line / Cautious
If results are in line with expectations, the market may react cautiously, reflecting uncertainty about future growth.
Miss
Should the company miss its targets, history suggests an average move of +7.48% in the negative direction, indicating significant market disappointment.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026